Cancer Epigenetics

被引:360
作者
Taby, Rodolphe [1 ]
Issa, Jean-Pierre J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA
关键词
ISLAND METHYLATOR PHENOTYPE; TUMOR-SUPPRESSOR GENES; RETINOIC ACID RECEPTOR; DNA METHYLATION; PROMOTER METHYLATION; CLINICAL-RESPONSE; PROSTATE-CANCER; LUNG-CANCER; 5-METHYLCYTOSINE CONTENT; MYELODYSPLASTIC SYNDROME;
D O I
10.3322/caac.20085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epigenetics refers to stable alterations in gene expression with no underlying modifications in the genetic sequence and is best exemplified by differentiation, in which multiple cell types diverge physiologically despite a common genetic code. Interest in this area of science has grown over the past decades, especially since it was found to play a major role in physiologic phenomena such as embryogenesis, imprinting, and X chromosome inactivation, and in disease states such as cancer. The latter had been previously thought of as a disease with an exclusive genetic etiology. However, recent data have demonstrated that the complexity of human carcinogenesis cannot be accounted for by genetic alterations alone, but also involves epigenetic changes in processes such as DNA methylation, histone modifications, and microRNA expression. In turn, these molecular alterations lead to permanent changes in the expression of genes that regulate the neoplastic phenotype, such as cellular growth and invasiveness. Targeting epigenetic modifiers has been referred to as epigenetic therapy. The success of this approach in hematopoietic malignancies validates the importance of epigenetic alterations in cancer, not only at the therapeutic level but also with regard to prevention, diagnosis, risk stratification, and prognosis. CA Cancer J Clin 2010;60:376-392. (C) 2010 American Cancer Society, Inc.
引用
收藏
页码:376 / 392
页数:17
相关论文
共 160 条
[1]  
Abe M, 2005, CANCER RES, V65, P828
[2]  
Aggerholm A, 1999, CANCER RES, V59, P436
[3]  
Ahuja N, 1998, CANCER RES, V58, P5489
[4]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[5]   The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression [J].
Ashburner, BP ;
Westerheide, SD ;
Baldwin, AS .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (20) :7065-7077
[6]   Histone methylation: Dynamic or static? [J].
Bannister, AJ ;
Schneider, R ;
Kouzarides, T .
CELL, 2002, 109 (07) :801-806
[7]   Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort [J].
Belinsky, SA ;
Liechty, KC ;
Gentry, FD ;
Wolf, HJ ;
Rogers, J ;
Vu, K ;
Haney, J ;
Kenned, TC ;
Hirsch, FR ;
Miller, Y ;
Franklin, WA ;
Herman, JG ;
Baylin, SB ;
Bunn, PA ;
Byers, T .
CANCER RESEARCH, 2006, 66 (06) :3338-3344
[8]   Gene promoter methylation in plasma and sputum increases with lung cancer risk [J].
Belinsky, SA ;
Klinge, DM ;
Dekker, JD ;
Smith, MW ;
Bocklage, TJ ;
Gilliland, FD ;
Crowell, RE ;
Karp, DD ;
Stidley, CA ;
Picchi, MA .
CLINICAL CANCER RESEARCH, 2005, 11 (18) :6505-6511
[9]   DNA METHYLTRANSFERASES [J].
BESTOR, TH ;
VERDINE, GL .
CURRENT OPINION IN CELL BIOLOGY, 1994, 6 (03) :380-389
[10]   Creation of genomic methylation patterns [J].
Bestor, TH ;
Tycko, B .
NATURE GENETICS, 1996, 12 (04) :363-367